Aberdeen Medical Science Innovation Portfolio, Series 12, Guggenheim Defined Portfolios, Series 2592
$9.87
+0.05 (+0.51%)
NAV as of Oct 14, 2026
Performance
- 1 Month
- -5.1%
- 3 Months
- -14.5%
Price return, based on split- and dividend-adjusted closing prices.
Risk
- Largest decline max drawdown, since May 2026
- -14.9%
Own CTMELX?
See how CTMELX contributes to your portfolio's return, allocation, and risk.
7-day free trial, then $9/month.